The IBD Drug Discovery and Development Unit's (IBD3) collaboration with Translational Genetics, Clinical Research and Basic Research enables us to identify potential disease-associated biological pathways in patient sub-populations for target discovery, biomarker identification and drug development.
These sub-populations include homogenous groups, or clusters, based on genetics, clinical history and medications. The clusters are also disease-specific and are identified by ethnicity. Our pool of patient samples is used to further research for Inflammatory Bowel Disease. Some of our patients stay in our program indefinitely, providing current samples as needed.